We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of MK0359 in Patients With Chronic Asthma (0359-013)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00482898
First Posted: June 5, 2007
Last Update Posted: May 27, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
  Purpose
A study to test the effect of MK0359 in lessening the symptoms of asthma as compared to placebo.

Condition Intervention Phase
Asthma Drug: MK0359 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Crossover Study Comparing the Effect of MK0359 and Placebo in Adult Patients With Chronic Asthma

Further study details as provided by Merck Sharp & Dohme Corp.:

Enrollment: 56
Study Start Date: September 2002
Study Completion Date: April 2003
Primary Completion Date: April 2003 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • You are between the ages of 18 and 45
  • You have had a history for at least a year of COPD symptoms
  • Your current asthma treatment is limited to short-acting beta-agonists(such as albuterol)
  • You have a history of smoking one pack of cigarettes per day for 7 years
  • You will not be away from home for more than 5 days during the study

Exclusion Criteria:

  • You are unwilling to limit your alcohol use to less than 5 drinks per week
  • You have been in a research study with an investigational drug or vaccine in the last 4 weeks
  • You have donated blood in the last 4 weeks
  • You have been hospitalized or had major surgery in the last 4 weeks
  • You have been treated in the emergency room within the last 4 weeks or hospitalized within the last 3 months for your asthma
  • You have a history of heart problems in the last 6 months
  • You have a history of stomach problems
  • You are unwilling to avoid grapefruit juice throughout the study
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00482898


Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

Publications:
Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00482898     History of Changes
Other Study ID Numbers: 0359-013
MK0359-013
2007_575
First Submitted: June 1, 2007
First Posted: June 5, 2007
Last Update Posted: May 27, 2015
Last Verified: May 2015

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases